A carregar...
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
INTRODUCTION: Interleukin (IL)-17 inhibitors are the most recent class of monoclonal antibodies approved by the FDA for psoriasis treatment. Preclinical and phase II studies of brodalumab, a high-affinity IL-17 receptor monoclonal antibody, have been encouraging. METHODS: We conducted a literature s...
Na minha lista:
| Publicado no: | Dermatol Ther (Heidelb) |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4906115/ https://ncbi.nlm.nih.gov/pubmed/27221323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-016-0121-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|